PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer. Market Analysis and Insights: Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market The global PARP (Poly ADP-ribose Polymerase) Inhibitors market size is projected to reach US$ 21490 million by 2027, from US$ 2861 million in 2020, at a CAGR of 32.8% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market in terms of revenue. On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global PARP (Poly ADP-ribose Polymerase) Inhibitors market. Global PARP (Poly ADP-ribose Polymerase) Inhibitors Scope and Market Size PARP (Poly ADP-ribose Polymerase) Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global PARP (Poly ADP-ribose Polymerase) Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type Olaparib Talazoparib Segment by Application Ovarian Cancer Breast Cancer Other By Region North America U.S. Canada Europe Germany France U.K. Italy Russia Nordic Rest of Europe Asia-Pacific China Japan South Korea Southeast Asia India Australia Rest of Asia Latin America Mexico Brazil Rest of Latin America Middle East & Africa Turkey Saudi Arabia UAE Rest of MEA By Company AbbVie Pfizer AstraZeneca GlaxoSmithKline Clovis Oncology Everest Pharmaceuticals
1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Olaparib 1.2.3 Talazoparib 1.3 Market by Application 1.3.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 O
